ADK.V - DIAGNOS Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.0350
0.0000 (-12.50%)
As of 11:04AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.0350
Open0.0350
Bid0.035 x 0
Ask0.040 x 0
Day's Range0.0350 - 0.0350
52 Week Range0.0300 - 0.1600
Volume50,000
Avg. Volume155,139
Market Cap6.063M
Beta (3Y Monthly)4.26
PE Ratio (TTM)N/A
EPS (TTM)-0.021
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire2 days ago

    DIAGNOS Announces Closing of Private Placement

    BROSSARD, Quebec, Dec. 12, 2018 -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health.

  • GlobeNewswire10 days ago

    DIAGNOS is announcing a collaboration with ÉTS on Automated detection and grading of Diabetic Retinopathy using Deep Convolutional Neural Networks, (CNN) a new generation of Deep Learning Technique  

    BROSSARD, Quebec, Dec. 04, 2018 -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues.

  • GlobeNewswire23 days ago

    DIAGNOS Announces Final Closing of Private Placement

    BROSSARD, Quebec, Nov. 21, 2018 -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health.

  • GlobeNewswire23 days ago

    DIAGNOS Enters into a Shares for Debt Transaction

    DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces today it has entered into a shares for debt arrangement in which the Corporation is issuing 900,000 common shares (each a “Share”), at a deemed price of $0.05 per Share, in settlement for interests payable in the amount of $45,000 on outstanding unsecured convertible notes (each a “Note”) totaling $900,000. Satisfying this outstanding indebtedness with shares was undertaken in order to preserve the Corporation’s cash for operational purposes. Two Note holders eligible to receive common shares as part of the shares for debt transaction are considered “related parties” of the Corporation within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”).

  • GlobeNewswirelast month

    DIAGNOS Announces Today the Addition of a Strategic Partner in the Country of Mexico

    DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today the addition of a strategic partner in the country of Mexico.  This agreement will enlarge the footprint coverage of DIAGNOS’ offering for monitoring diabetic patients through our first partner in that country. “Today we all (my family and I), accepted unanimously to go with DIAGNOS in this adventure, we truly believe both of us will do great and together will achieve important objectives”, declares Quim. “Mr. Andre Larente visited me in Monterrey city, my hometown at my brand new office, we clicked right away because we both are men of one vision: to provide the best diagnostic technology to prevent and leverage the health quality of people.” “I also met Mr. Georges Herbert Chairman of DIAGNOS Inc, during his visit to Mexico City.

  • GlobeNewswirelast month

    DIAGNOS Announces Closing of Private Placement

    DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces the closing of a private placement (“Private Placement”) of 20,660,000 units (each a “Unit”) issued at $0.05 per Unit for gross proceeds of $1,033,000. The Private Placement was initially announced on November 6, 2018 for gross proceeds of up to $808,000.

  • GlobeNewswirelast month

    DIAGNOS Announces Private Placement of Common Stocks and Stock Warrants

    DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces a private placement (“Private Placement”) of up to 16,160,000 units (each a “Unit”) issued at $0.05 per Unit for gross proceeds of up to $808,000. It is expected that one participant in the Private Placement will become a “related party” of DIAGNOS within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The participant will exercise, as a result of the Private Placement, control up to 19.10% of the common shares of DIAGNOS.

  • GlobeNewswirelast month

    DIAGNOS Announces Closing of Private Placement of Common Stocks and Stock Warrants

    BROSSARD, Québec, Nov. 01, 2018 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence, announces the closing of a private placement (“Private Placement”) of 10,000,000 units (each a “Unit”) issued at $0.05 per Unit for gross proceeds of $500,000. The Private Placement was initially announced on October 24th, 2018 for gross proceeds of up to $400,000.

  • GlobeNewswire3 months ago

    DIAGNOS to Provide Retinal Image Analysis using its AI Technology to 20/20NOW, the Leading Ocular Telehealth Provider in the United States

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today a three-year agreement to provide its CARA (Computer Assisted Retina Analysis) to 20/20NOW. 20/20NOW will use CARA to upload their retinal images and retrieve the results after analysis by our algorithms to detect anomalies caused by diabetic retinopathy in real time. Identifying diabetic retinopathy (“DR”) in its early stages, when it’s most treatable, is critical to prevent blindness and help at lowering health care costs.